Current Bladder Dysfunction Reports

, Volume 14, Issue 2, pp 83–89 | Cite as

Chronic Prostatitis/Chronic Pelvic Pain Syndrome: a Literature Review of NIH III Prostatitis

  • Thomas Farmer
  • Max Johnston
  • Alina Milica
  • Richard Hindley
  • Amr EmaraEmail author
Inflammatory/Infectious Bladder Disorders (MS Mourad, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Inflammatory/Infectious Bladder Disorders


Purpose of Review

This review seeks to review up to date literature surrounding the chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) to provide an overview of the subject. The review includes current understandings of the syndrome, the use of UPOINT, novel treatment strategies and future targets for management.

Recent Findings

Using the US National Institute of Health Chronic Prostatitis Symptom Index helps clinicians to monitor prostatitis symptoms, whilst using UPOINT as guidance of therapies based on patient phenotype(s) has advanced our ability to treat patients suffering with CP/CPPS. Furthermore, novel treatments look beyond traditional prostatic targets to treat CP/CPPS.


Whilst the use of UPOINT has opened up new targets for the treatment of CP/CPPS, more work is needed to both improve the quality of trials assessing them, as well as further elucidate the underlying pathophysiology behind this troublesome syndrome.


Chronic prostatitis Chronic pelvic pain syndrome UPOINT Extra-prostatic targets 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Sandhu J, Tu HYV. Recent advances in managing chronic prostatitis/chronic pelvic pain syndrome. F1000Res. 2017;6:F1000 Faculty Rev-1747.CrossRefGoogle Scholar
  2. 2.
    Nickel JC, Shoskes DA. Phenotypic approach to the management of the chronic prostatitis/chronic pelvic pain syndrome. BJUI. 2010;106:1252–63.CrossRefGoogle Scholar
  3. 3.
    Nickel JC. The three as of chronic prostatitis therapy: antibiotics, α-blockers and anti-inflammatories. What is the evidence? BJUI. 2004;94:1230–3.CrossRefGoogle Scholar
  4. 4.
    Thankkinstian A, Attia J, Anothaisintawee T, Nickel JC. α-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome. BJUI. 2012;110:1014–22.CrossRefGoogle Scholar
  5. 5.
    Krieger JN, Lee SW, Jeon J, Cheah PY, Liong ML, Riley DE. Epidemiology of prostatitis. Int J Antimicrob Agents. 2007;31(Suppl1):S85–90.Google Scholar
  6. 6.
    •• Anderson RU, Wise D, Nathanson BH. Chronic prostatitis and/or chronic pelvic pain as a psychoneuromuscular disorder - a meta-analysis. Urology. 2018;120:23–9 Current evidence showing benefit of treating CP/CPPS as psychoneuromuscular disorder. CrossRefGoogle Scholar
  7. 7.
    DeWitt-Foy ME, Nickel JC, Shoskes DA. Management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol Focus. 2019;5(1):2–4.Google Scholar
  8. 8.
    Shoskes DA, Nickel JC, Dolinga R, Prots D. Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom severity. Urology. 2009;73(3):538–42.CrossRefGoogle Scholar
  9. 9.
    Rees J, Abrahams M, Doble A, Cooper A. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJUI. 2015;116:509–25.CrossRefGoogle Scholar
  10. 10.
    Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. CID. 2010;50:1641–52.CrossRefGoogle Scholar
  11. 11.
    Tsivkovskii R, Sabet M, Tarazi Z, Griffith DC, Lomovskaya O, Dudley MN. Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: implications for aerosol MP-376 (levofloxacin solution for inhalation) treatment of chronic pulmonary infections. FEMS Immunol Med Microbiol. 2011;61(2):141–6.CrossRefGoogle Scholar
  12. 12.
    Ogino H, Fujii M, Ono M, Maezawa K, Kizu J, Hori S. In vivo and in vitro effects of fluoroquinolones on lipopolysaccharide-induced pro-inflammatory cytokine production. J Infect Chemother. 2009;15(3):168–73.CrossRefGoogle Scholar
  13. 13.
    Roehrborn CG. Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective α-blocker. Urology. 2001;58(6):55–63.CrossRefGoogle Scholar
  14. 14.
    Kirby RS, Lowe D, Bultitude MI, Shuttleworth KE. Intraprostatic urinary reflux: an etiological factor in abacterial prostatitis. Br J Urol. 1982;54:729–31.CrossRefGoogle Scholar
  15. 15.
    Duclos AJ, Lee CT, Shoskes DA. Current treatment options in the management of chronic prostatitis. Ther Clin Risk Manag. 2007;3(4):507–12.Google Scholar
  16. 16.
    Hochreiter WW. Anti-inflammatory therapies for chronic prostatitis. Eur Urol Suppl. 2003;2(2):30–3.CrossRefGoogle Scholar
  17. 17.
    Anothaisintawee T, Attia J, Nickel CJ, Thammakraisorn S, et al. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA. 2011;305(1):78–86.CrossRefGoogle Scholar
  18. 18.
    Wagenlehner FM, Schneider H, Ludwig M, Schnitker J, et al. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol. 2009;56(3):544–51.CrossRefGoogle Scholar
  19. 19.
    Nickel JC, Shoskes DA, Wagenlehner FM. Management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): the studies, the evidence, and the impact. World J Urol. 2013;31(4):747–53.CrossRefGoogle Scholar
  20. 20.
    Bates SM, Hill VA, Anderson JB, Chapple CR, et al. A prospective, randomized, double-blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome. BJU Int. 2007;99(2):355–9.Google Scholar
  21. 21.
    Kessler TM, Mordasini L, Weisstanner C, Jüni P, da Costa BR, Wiest R, et al. Sono-electro-magnetic therapy for treating chronic pelvic pain syndrome in men: a randomized, placebo-controlled, double-blind trial. PLoS One. 2014;9(12):e113368.CrossRefGoogle Scholar
  22. 22.
    Ateya A, Fayez A, Hani R, Zohdy W, Gabbar MA, Shamloul R. Evaluation of prostatic massage in treatment of chronic prostatitis. Urology. 2006;67(4):674–8.CrossRefGoogle Scholar
  23. 23.
    • Magri V, Wagenlehner F, Perletti G, Schneider S. Use of the UPOINT chronic prostatitis/chronic pelvic pain syndrome classification in European patient cohorts: sexual function domain improves correlations. J Urol. 2010;184(6):2339–45 Creation of sexual function domain further helps corrolate UPOINT to clinical phenotyping. CrossRefGoogle Scholar
  24. 24.
    Shoskes DA, Nickel JC, Kattan MW. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT. Urology. 2010;75(6):1249–53.CrossRefGoogle Scholar
  25. 25.
    Guan X, Zhao C, Ou ZY, Wang L, et al. Use of the UPOINT phenotype system in treating Chinese patients with chronic prostatitis/chronic pelvic pain syndrome: a prospective study. Asian J Androl. 2015;17(1):120–3.CrossRefGoogle Scholar
  26. 26.
    Qin Z, Wu J, Zhou J, Liu Z. Systematic review of acupuncture for chronic prostatitis/chronic pelvic pain syndrome. Medicine (Baltimore). 2016;95(11):e3095.CrossRefGoogle Scholar
  27. 27.
    • Liu BP, Wang YT, Chen SD. Effect of acupuncture on clinical symptoms and laboratory indicators for chronic prostatitis/chronic pelvic pain syndrome: a systematic review and meta-analysis. Int Urol Nephrol. 2016;48(12):1977–91 Meta analysis suggesting the benefits of use of acupuncture in CP/CPPS. CrossRefGoogle Scholar
  28. 28.
    Zhang R, Chomistek AK, Dimitrakoff JD, Giovannucci EL, et al. Physical activity and chronic prostatitis/chronic pelvic pain syndrome. Med Sci Sports Exerc. 2015;47(4):757–64.CrossRefGoogle Scholar
  29. 29.
    Giubilei G, Mondaini N, Minervini A, Saieva C, Lapini A, Serni S, et al. Physical activity of men with chronic prostatitis/chronic pelvic pain syndrome not satisfied with conventional treatments--could it represent a valid option? The physical activity and male pelvic pain trial: a double-blind, randomized study. J Urol. 2007;177(1):159–65.CrossRefGoogle Scholar
  30. 30.
    Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol. 2005;98(4):1154–62.CrossRefGoogle Scholar
  31. 31.
    Nickel JC, Tripp DA, Chuai S, Litwin, et al. Psychosocial variables affect the quality of life of men with chronic prostatitis/chronic pelvic pain syndrome. BJUI. 2007;101:59–64.Google Scholar
  32. 32.
    Tripp DA, Nickel CJ, Wang Y, Litwin MS, et al. Catastrophizing and pain-contingent rest predict patient adjustment in men with chronic prostatitis/chronic pelvic pain syndrome. J Pain. 2006;7(10):697–708.CrossRefGoogle Scholar
  33. 33.
    Brünahl CA, Klotz SGR, Dybowski C, Riegel B. Combined cognitive-behavioural and physiotherapeutic therapy for patients with chronic pelvic pain syndrome (COMBI-CPPS): study protocol for a controlled feasibility trial. Trials. 2018;19(1):20.CrossRefGoogle Scholar
  34. 34.
    Magistro G, Wagenlehner FM, Grabe M, Weidner W, et al. Contemporary management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol. 2016;69(2):286–97.CrossRefGoogle Scholar
  35. 35.
    Nickel CJ, Shoskes DA, Roehrborn CG, Moyad M. Nutraceuticals in prostate disease: the urologist’s role. Rev Urol. 2008;10(3):192–206.Google Scholar
  36. 36.
    Shoskes DA, Zeitlin SI, Shahed A, Rajfer J. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology. 1999;54(6):960–3.CrossRefGoogle Scholar
  37. 37.
    Shahed AR, Shoskes DA. Oxidative stress in prostatic fluid of patients with chronic pelvic pain syndrome: correlation with gram positive bacterial growth and treatment response. J Androl. 2000;21(5):669–75.Google Scholar
  38. 38.
    • Morgia G, Russo GI, Urzi D, Privitera S, et al. A phase II, randomized, single-blinded, placebo-controlled clinical trial on the efficacy of Curcumina and Calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III. Arch Ital Urol Androl. 2017;89(2):110–3 RCT showing benefit of using phytotherapies for CP/CPPS. CrossRefGoogle Scholar
  39. 39.
    Jin C, Chen Z, Zhang J. Meta-analysis of the efficacy of Ningmitai capsule on the treatment of chronic prostatitis in China. Medicine(Baltimore). 2018;97(33):e11840.Google Scholar
  40. 40.
    Zhang K, Zeng X, Chen Y, Zhao R, Wang H, Wu J. Therapeutic effects of Qian-Yu decoction and its three extracts on carrageenan-induced chronic prostatitis/chronic pelvic pain syndrome in rats. BMC Complement Altern Med. 2017;17(1):75.CrossRefGoogle Scholar
  41. 41.
    Barnes RW, Hadley HL, O’Donoghue EP. Transurethral resection of the prostate for chronic bacterial prostatitis. Prostate. 1982;3(3):215–9.CrossRefGoogle Scholar
  42. 42.
    •• Chopra S, Satkunasivam R, Aron M. Feasibility of robotic radical prostatectomy for medication refractory chronic prostatitis/chronic pelvic pain syndrome: initial results. Indian J Urol. 2016;32(3):238–41 Case report on the use of surgery for CP/CPPS in appropriately selected patients. CrossRefGoogle Scholar
  43. 43.
    Frazier HA, Spalding TH, Paulson DF. Total prostatoseminal vesiculectomy in the treatment of debilitating perineal pain. J Urol. 1992;148(2):409–11.CrossRefGoogle Scholar
  44. 44.
    Krongrad A, Shenghan L. Laparoscopic prostatectomy for severely symptomatic treatment-refractory chronic prostatitis: preliminary observations from an ongoing phase II clinical trial. UroToday Int J. 2011;4(2):1944–5784.CrossRefGoogle Scholar
  45. 45.
    Franco JVA, Turk T, Xiao YT, Iakhno S, et al. Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review. Cochrane Database Syst Rev. 2018;1:CD01255.Google Scholar
  46. 46.
    Abdel-Meguid TA, Mosli HA, Farsi H, Alsayyad A, Tayib A, Sait M, et al. Treatment of refractory category III nonbacterial chronic prostatitis/chronic pelvic pain syndrome with intraprostatic injection of onabotulinumtoxin A: a prospective controlled study. Can J Urol. 2018;25(2):9273–80.Google Scholar
  47. 47.
    Hong H, Kim CS, Maeng S. Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutr Res Pract. 2009;3(4):323–7.CrossRefGoogle Scholar
  48. 48.
    Tantawy SA, Elgohary HM, Kamel DM. Trans-perineal pumpkin seed oil phonophoresis as an adjunctive treatment for chronic nonbacterial prostatitis. Res Rep Urol. 2018;10:95–101.Google Scholar
  49. 49.
    Hajighorbani M, Ahmadi-Hamedani M, Shahab E, Hayati F, et al. Evaluation of the protective effect of pentoxifylline on carrageenan-induced chronic non-bacterial prostatitis in rats. Inflammopharmacology. 2017;25(3):343–50.CrossRefGoogle Scholar
  50. 50.
    Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids. 2008;73(3):233–44.CrossRefGoogle Scholar
  51. 51.
    Tiwari-Woodruff S, Voskuhl RR. Neuroprotective and anti-inflammatory effects of estrogen receptor ligand treatment in mice. J Neurol Sci. 2009;286(1–2):81–5.CrossRefGoogle Scholar
  52. 52.
    Acar D, Cayan S, Aktaş S, Tek M. The effect of tamoxifen on bladder functions and histology, and the role of estrogen receptor beta in a rat chemical cystitis model. Neurourol Urodyn. 2007;26(2):309–16.CrossRefGoogle Scholar
  53. 53.
    •• Mizoguchi S, Mori K, Wang Z, Liu T, Funahashi Y, Sato F, et al. Effects of estrogen receptor β stimulation in a rat model of non-bacterial prostatic inflammation. Prostate. 2017;77(7):803–11 New research with promising novel target for management of CP/CPPS. CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Thomas Farmer
    • 1
  • Max Johnston
    • 2
  • Alina Milica
    • 1
  • Richard Hindley
    • 1
  • Amr Emara
    • 1
    • 3
    Email author
  1. 1.Basingstoke and North Hampshire HospitalBasingstokeUK
  2. 2.Royal Surrey County HospitalGuildfordUK
  3. 3.Urology DepartmentAin Shams UniversityCairoEgypt

Personalised recommendations